SLC22A2 and type 2 diabetes mellitus: In contrast, there was no statistically significant association between genetically predicted inhibition of SLC22A2 (OR = 0.95, 95% CI: 0.61–1.48, p = 0.84) or CLDN14 (OR = 1.56, 95% CI: 0.71–2.20, p = 0.84) and the risk of T2D (Table 2).